Evidence map›Paper›PMID 26000262›Full record

ReviewMedical journal of the Islamic Republic of Iran2015

Stem cell-based approach for the treatment of Parkinson's disease.

Parisa Goodarzi, Hamid Reza Aghayan, Bagher Larijani, Masoud Soleimani, Ahmad-Reza Dehpour, Mehrnaz Sahebjam, Firoozeh Ghaderi, Babak Arjmand

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Medical journal of the Islamic Republic of Iran, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Stem Cell-Based Modeling Protocol for Parkinson's Disease.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. The Fingerprints of Biomedical Science in Internal Medicine.Advances in experimental medicine and biology · 2022
    Article
  14. Review
  15. Review
  16. Review
  17. Regenerative Medicine Perspectives in Polycystic Ovary Syndrome.Advances in experimental medicine and biology · 2021
    Article
  18. Review
  19. Article
  20. GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Parisa GoodarziMSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. goudarzi.p@iums.ac.ir.
Hamid Reza AghayanMD, PhD, Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. hr_aghayan@farabi.tums.ac.ir.
Bagher LarijaniMD, Endocrinology and Metabolism Research Center , Endocrinology and Metabolism Research Institute, Tehran University of Medical sciences, Tehran, Iran. Larijanib@tums.ac.ir.
Masoud SoleimaniPhD, Hematology Department, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran. soleim_m@modares.ac.ir.
Ahmad-Reza DehpourPhD, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com.
Mehrnaz SahebjamBSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. mehrsahebjam44@gmail.com.
Firoozeh GhaderiBSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. firozehghaderi@yahoo.com.
Babak ArjmandMD, PhD, GMP-Compliant Stem Cell Facility, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Shariati Hospital, North Kargar, Tehran, Iran. b_arjmand@farabi.tums.ac.ir.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRShariati Hospital · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5 times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are common approaches to PD, while all of them focused on reducing the symptoms. Therefore, regenerative medicine based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal (MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related ethical and immunological concerns . Further studies are needed to answer some crucial questions about the different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evaluation in both basic and clinical study areas.

Indexed as

Cellular therapyNeurodegenerative diseasesParkinson’s diseaseStem cell

Identifiers

PMID26000262
PMCPMC4431356
OpenAlexW2109185691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.